分類: 奥博资本

OrbiMed Promotes Mona Ashiya to General Partner

Posted on by Dan Bendlin

NEW YORK, July 22, 2025 – OrbiMed, a leading global healthcare investment firm, today announced the promotion of Mona Ashiya, Ph.D., to general partner. Ashiya joins the company’s eight existing general partners as a management company owner and leader of the firm.

“Mona is a recognized leader in biotechnology investing,” OrbiMed Managing Partner Carl Gordon said. “She has made significant contributions to the industry and to OrbiMed. We look forward to continuing to work with her to start and grow the next generation of exciting biotechnology companies.”

Since joining OrbiMed in 2010, Ashiya has focused on venture capital and special situations opportunities. She has established herself as a leading, consistently successful investor in the life sciences venture capital ecosystem. Ashiya led OrbiMed’s investments in many industry-leading companies, including Sierra Oncology, Disc Medicine and ProfoundBio. She has also advanced the growth of OrbiMed’s special situations investment practice, leading numerous PIPE investments during her tenure.

About OrbiMed

OrbiMed is a leading healthcare investment firm, with over $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 130 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets. For more information, please visit www.orbimed.com or follow us on X @OrbiMed.

Contact
Carter Neild, CFA
Phone: (212) 739.6400
Email: NeildC@OrbiMed.com

OrbiMed Raises Over $4.3 Billion Across Private Investment Funds

Posted on by orbimed

NEW YORK, October 24, 2023 – OrbiMed, a global healthcare investment firm, is pleased to announce it has raised more than $4.3 billion in commitments for its latest private investment funds, including OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV.

Consistent with their predecessors, these new funds enable OrbiMed to invest globally, from seed stage for start-ups incubated by OrbiMed through growth capital opportunities. OrbiMed works closely with its portfolio companies to provide tailored financing solutions, which can include equity, credit and royalty-based financing. OrbiMed focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics and technologyenabled healthcare services.

OrbiMed is led by its 21 partners, with a growing team exceeding 130 professionals that contribute diverse, complementary skills across company incubation, strategy, operations and finance. The firm’s professionals are based in a dozen global locations across key healthcare markets in North America, Europe and Asia.

Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices.

“OrbiMed is deeply appreciative of the continued support we’ve received from many long-standing partners who’ve invested in these funds,” said Carter Neild, a Managing Partner of OrbiMed. “We will endeavor to meet our partners’ high expectations in the coming years.”

About OrbiMed

OrbiMed is a leading healthcare investment firm, with over $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets. For more information, please visit www.orbimed.com. Follow us on X (formerly Twitter) @OrbiMed.

Contact
Carter Neild, CFA
Phone: (212) 739.6400
Email: NeildC@OrbiMed.com

OrbiMed Expands to Europe, Opens London Office

Posted on by orbimed

NEW YORK, May 3, 2023 – OrbiMed is excited to announce the opening of its inaugural London office, located at 22a St. James’s Square. This expansion is a logical culmination of OrbiMed’s many decades of commitment to the European life sciences industry.

“With approximately $1.5 billion currently invested in 50 public or private European companies, OrbiMed is an established leader in the European life sciences industry,” stated Managing Partner Carl Gordon. “We look forward to building on this strong foundation to provide even greater local support for our network of European portfolio companies, entrepreneurs, and limited partners.” Matthew Rizzo, General Partner of OrbiMed said, “As part of this expansion, we will accelerate the availability of credit and financing solutions to support healthcare growth and innovation across Europe.”

OrbiMed’s European business activities include serving as the Portfolio Manager for the Worldwide Healthcare Trust PLC and the Biotech Growth Trust PLC, which currently boast more than $3 billion in combined assets under management.

Dimitrios Weedon, Managing Director, has joined OrbiMed as the initial London-based team member, focusing on structured private credit, growth equity, and royalty monetization opportunities. Further team additions are planned to focus on public and private equity investments. Dimitrios can be reached by email: WeedonD@OrbiMed.com.

About OrbiMed

OrbiMed is a leading healthcare investment firm, with over $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

Contact
Carter Neild, CFA
Phone: (212) 739.6400
Email: NeildC@OrbiMed.com